LifeSciences BC Recruits a Dedicated Medical Device Sector Specialist and Event Manager, Dr. Wei Liu
LifeSciences British Columbia is pleased to announce the most recent addition to our team, Dr. Wei Liu who will act as a Medical Device Sector Specialist and Event Manager.
WEX Reconstitutes Scientific Advisory Board
Vancouver, BC - May 25, 2007- WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announces that the Company has reconstituted its Scientific Advisory Board and appointed an outstanding group of physicians and scientists to its new Scientific Advisory Board. These five advisory board members will provide WEX senior management with scientific and medical advice on the Company’s drug development plans and strategies.
Dr. Anthony Tolcher Joins Chemokine's Clinical Advisory Board
Vancouver, B.C -May, 11, 2007-Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics), has joined its oncology Clinical Advisory Board. Comprised of leading oncologists and translational researchers, Chemokine's advisory boards play an important role in guiding and participating in Chemokine's clinical development programs.
Aspreva Reports Results For First Quarter 2007 and Announces Leadership Transition of Founding CEO Richard Glickman
Victoria, B.C -May 02, 2007- Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), today released financial results for the first quarter ended March 31, 2007. First quarter revenues were $59.3 million with net income and earnings per fully diluted share of $36.4 million and $1.03, respectively. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.
QLT strengthens its expertise in ocular by adding David A. Saperstein M.D. as interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board
Vancouver, B.C -May 1, 2007- QLT Inc. announced today that David A. Saperstein, M.D. will be joining QLT as a consultant and interim Chief Medical Officer and Paul L. Kaufman, M.D. as Head of our Ocular Scientific Advisory Board.Aspreva chief to retire for personal reasons
Renowned International Scientific Leader, Dr. Pierre Meulien Joins Genome BC Team
Vancouver, BC -May 1, 2007- Dr. Alan Winter, President and CEO of Genome British Columbia today announced the appointment of Dr. Pierre Meulien as Chief Scientific Officer for Genome British Columbia.
BioLytical TM Laboratories Recruits Carl Roy as President and CEO
Vancouver, B.C -April 30, 2007– bioLyticalTM Laboratories (‘bioLyticalTM) is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO.
